{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:15:34Z","timestamp":1792732534439,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006470","name":"Aristotle University of Thessaloniki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study is an overview of systematic reviews focusing on adverse events of antimyeloma treatments. It provides a systematic description of adverse events as they are reported in the systematic reviews as well as a critical appraisal of included reviews. We conducted a comprehensive literature search in the most widely used electronic databases looking for systematic reviews that had an adverse event of an antimyeloma treatment intervention as primary outcome. Two independent reviewers conducted selection of included studies and data extraction on predesigned online forms and assessed study quality using AMSTAR 2. Overall corrected covered area (CCA) was calculated to examine the overlap of primary studies across systematic reviews. After screening eligible studies, 23 systematic reviews were included in this overview. Seven reviews with overall CCA of 14.7% examined cardiovascular adverse events of different drugs, including immunomodulatory drugs and proteasome inhibitors (mainly carfilzomib). Nine focused on infections, presenting with overall CCA of 5.8%, each one focused on a different drug or drug class. Three studied thromboembolism in patients treated either with lenalidomide, any immunomodulatory drug, or with daratumumab and had an overall CCA equal to 1.5%. Four more reviews focused on bortezomib-associated neurotoxicity, carfilzomib-associated renal toxicity, or second primary malignancies as an adverse event of lenalidomide or anti-CD38 monoclonal antibody treatment. The quality of included studies as judged by AMSTAR 2 was mostly critically low. Absence of a priori registered protocol and formal assessment of risk of bias of included primary studies were the most common shortcomings. Reporting of antimyeloma drug-associated toxicity is supported by multiple systematic reviews; nevertheless, methodological quality of existing reviews is mostly low.<\/jats:p>","DOI":"10.1007\/s00277-023-05517-7","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T03:01:41Z","timestamp":1699412501000},"page":"2681-2697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-2241","authenticated-orcid":false,"given":"Maria","family":"Mainou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Bougioukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Malandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Liakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippos","family":"Klonizakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Avgerinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Betinna","family":"Haidich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"5517_CR1","doi-asserted-by":"publisher","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26590","DOI":"10.1002\/ajh.26590"},{"key":"5517_CR2","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","volume":"22","author":"O Landgren","year":"2016","unstructured":"Landgren O, Rajkumar SV (2016) New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res 22:5428\u20135433. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0866","journal-title":"Clin Cancer Res"},{"key":"5517_CR3","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S0140-6736(21)00274-9","volume":"397","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2021) Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet 397:1620\u20131621. https:\/\/doi.org\/10.1016\/S0140-6736(21)00274-9","journal-title":"Lancet"},{"key":"5517_CR4","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/S2352-3026(21)00024-7","volume":"8","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V (2021) Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol 8:e299\u2013e304. https:\/\/doi.org\/10.1016\/S2352-3026(21)00024-7","journal-title":"Lancet Haematol"},{"key":"5517_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.critrevonc.2017.03.014","volume":"113","author":"PM Aguiar","year":"2017","unstructured":"Aguiar PM, de Mendon\u00e7a LT, Colleoni GWB, Storpirtis S (2017) Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses. Crit Rev Oncol Hematol 113:195\u2013212. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.014","journal-title":"Crit Rev Oncol Hematol"},{"key":"5517_CR6","doi-asserted-by":"publisher","unstructured":"Methods R, Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S  PRISMA harms checklist: improving harms reporting in systematic reviews. https:\/\/doi.org\/10.1136\/bmj.i157","DOI":"10.1136\/bmj.i157"},{"key":"5517_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jclinepi.2021.10.023","volume":"143","author":"R Qureshi","year":"2022","unstructured":"Qureshi R, Mayo-Wilson E, Li T (2022) Harms in Systematic Reviews Paper 1: an introduction to research on harms. J Clin Epidemiol 143:186\u2013196. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.10.023","journal-title":"J Clin Epidemiol"},{"key":"5517_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jclinepi.2022.11.003","volume":"153","author":"KI Bougioukas","year":"2023","unstructured":"Bougioukas KI, Pamporis K, Vounzoulaki E, Karagiannis T, Haidich A-B (2023) Types and associated methodologies of overviews of reviews in health care: a methodological study with published examples. J Clin Epidemiol 153:13\u201325. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.11.003","journal-title":"J Clin Epidemiol"},{"key":"5517_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2018.10.005","volume":"106","author":"KI Bougioukas","year":"2019","unstructured":"Bougioukas KI, Bouras E, Apostolidou-Kiouti F, Kokkali S, Arvanitidou M, Haidich A-B (2019) Reporting guidelines on how to write a complete and transparent abstract for overviews of systematic reviews of health care interventions. J Clin Epidemiol 106:70\u201379. https:\/\/doi.org\/10.1016\/j.jclinepi.2018.10.005","journal-title":"J Clin Epidemiol"},{"key":"5517_CR10","doi-asserted-by":"publisher","unstructured":"Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, Sep\u00falveda D, Mckenzie JE, Scott SD, Robinson KA, Matthias K, Bougioukas KI, Fusar P, Moss SJ, Hartling L  Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. 17. https:\/\/doi.org\/10.1136\/bmj-2022-070849","DOI":"10.1136\/bmj-2022-070849"},{"key":"5517_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.JCLINEPI.2017.10.002","volume":"93","author":"KI Bougioukas","year":"2018","unstructured":"Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich AB (2018) Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. J Clin Epidemiol 93:9\u201324. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2017.10.002","journal-title":"J Clin Epidemiol"},{"key":"5517_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2020.12.004","volume":"132","author":"KI Bougioukas","year":"2021","unstructured":"Bougioukas KI, Vounzoulaki E, Mantsiou CD, Savvides ED, Karakosta C, Diakonidis T, Tsapas A, Haidich A-B (2021) Methods for depicting overlap in overviews of systematic reviews: an introduction to static tabular and graphical displays. J Clin Epidemiol 132:34\u201345. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.12.004","journal-title":"J Clin Epidemiol"},{"key":"5517_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","volume":"67","author":"D Pieper","year":"2014","unstructured":"Pieper D, Antoine S-L, Mathes T, Neugebauer EAM, Eikermann M (2014) Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol 67:368\u2013375. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.11.007","journal-title":"J Clin Epidemiol"},{"key":"5517_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/jrsm.1610","volume":"14","author":"KI Bougioukas","year":"2023","unstructured":"Bougioukas KI, Diakonidis T, Mavromanoli AC, Haidich A (2023) <scp>ccaR<\/scp>\u2009: a package for assessing primary study overlap across systematic reviews in overviews. Res Synth Methods 14:443\u2013454. https:\/\/doi.org\/10.1002\/jrsm.1610","journal-title":"Res Synth Methods"},{"key":"5517_CR15","doi-asserted-by":"publisher","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA (2017) AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358. https:\/\/doi.org\/10.1136\/bmj.j4008","DOI":"10.1136\/bmj.j4008"},{"key":"5517_CR16","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"5517_CR17","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Chapter 7: Considering bias and conflicts of interest among the included studies. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021), The Cochrane Collaboration. Available from www.training.cochrane.org\/handbook. Accessed 26 Oct 2023"},{"key":"5517_CR18","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366. https:\/\/doi.org\/10.1136\/BMJ.L4898","DOI":"10.1136\/BMJ.L4898"},{"key":"5517_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"5517_CR20","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/doi.org\/10.1136\/BMJ.N71","DOI":"10.1136\/BMJ.N71"},{"key":"5517_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cardfail.2020.07.006","volume":"27","author":"MR Rahman","year":"2021","unstructured":"Rahman MR, Ball S, Paz P, Elmassry M, Vutthikraivit W, Bandyopadhyay D, Lavie CJ, Fonarow GC (2021) Heart failure with carfilzomib in patients with multiple myeloma: a meta-analysis of randomized controlled trials. J Card Fail 27:610\u2013612. https:\/\/doi.org\/10.1016\/j.cardfail.2020.07.006","journal-title":"J Card Fail"},{"key":"5517_CR22","doi-asserted-by":"publisher","unstructured":"Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, O\u2019Quinn R, Cohen AD, Stadtmauer EA, Ky B, Weiss BM (2018) Carfilzomib-associated cardiovascular adverse events a systematic review and meta-analysis. JAMA Oncol 4. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4519","DOI":"10.1001\/jamaoncol.2017.4519"},{"key":"5517_CR23","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","volume":"59","author":"C Shah","year":"2018","unstructured":"Shah C, Bishnoi R, Jain A, Bejjanki H, Xiong S, Wang Y, Zou F, Moreb JS (2018) Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma 59:2557\u20132569. https:\/\/doi.org\/10.1080\/10428194.2018.1437269","journal-title":"Leuk Lymphoma"},{"key":"5517_CR24","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/DDDT.S159818","volume":"12","author":"F Zhao","year":"2018","unstructured":"Zhao F, Yang B, Wang J, Zhang R, Liu J, Yin F, Xu W, He C (2018) Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib. Drug Des Devel Ther 12:1525\u20131531. https:\/\/doi.org\/10.2147\/DDDT.S159818","journal-title":"Drug Des Devel Ther"},{"key":"5517_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1871529X21666210412113017","volume":"21","author":"A Latif","year":"2021","unstructured":"Latif A, Kapoor V, Lateef N, Ahsan MJ, Usman RM, Malik SU, Ahmad N, Rosko N, Rudoni J, William P, Khouri J, Anwer F (2021) Incidence and management of carfilzomib-induced cardiovascular toxicity; a systematic review and meta-analysis. Cardiovasc Hematol Disord Drug Targets 21:30\u201345. https:\/\/doi.org\/10.2174\/1871529X21666210412113017","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"5517_CR26","doi-asserted-by":"publisher","first-page":"46593","DOI":"10.18632\/oncotarget.16235","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, YinHui T, Yunliang Z, Sun H (2017) Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 8:46593\u201346600. https:\/\/doi.org\/10.18632\/oncotarget.16235","journal-title":"Oncotarget"},{"key":"5517_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, Van Der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P et al (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 15:333\u2013342. https:\/\/doi.org\/10.1016\/S1470-2045(13)70609-0","journal-title":"Lancet Oncol"},{"key":"5517_CR28","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/cncr.32682","volume":"126","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS (2020) Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis. Cancer 126:1640\u20131650. https:\/\/doi.org\/10.1002\/cncr.32682","journal-title":"Cancer"},{"key":"5517_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M, Le Gal G, Tay J, Wu C, Lee AY (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9:653\u2013663. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04215.x","journal-title":"J Thromb Haemost"},{"key":"5517_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00277-018-3284-y","volume":"97","author":"M Chen","year":"2018","unstructured":"Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B (2018) Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies. Ann Hematol 97:925\u2013944. https:\/\/doi.org\/10.1007\/s00277-018-3284-y","journal-title":"Ann Hematol"},{"key":"5517_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hon.2959","volume":"40","author":"A Das","year":"2022","unstructured":"Das A, Dasgupta S, Gong Y, Shah UA, Fradley MG, Cheng RK, Roy B, Guha A (2022) Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials. Hematol Oncol 40:233\u2013242. https:\/\/doi.org\/10.1002\/hon.2959","journal-title":"Hematol Oncol"},{"key":"5517_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","volume":"67","author":"BW Teh","year":"2016","unstructured":"Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA (2016) Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer 67:21\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.025","journal-title":"Eur J Cancer"},{"key":"5517_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s12185-020-02954-2","volume":"112","author":"J Wang","year":"2020","unstructured":"Wang J, Kim Y (2020) Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis. Int J Hematol 112:650\u2013657. https:\/\/doi.org\/10.1007\/s12185-020-02954-2","journal-title":"Int J Hematol"},{"key":"5517_CR34","doi-asserted-by":"publisher","unstructured":"Yarlagadda N, Gundarlapalli S, Sharma S, Suelzer E, Abid MB, Abdallah AO, Schinke C, Atrash S, Mohan M (2021) Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: a meta-analysis of randomized control trials. Leuk Res 110. https:\/\/doi.org\/10.1016\/j.leukres.2021.106714","DOI":"10.1016\/j.leukres.2021.106714"},{"key":"5517_CR35","doi-asserted-by":"publisher","unstructured":"Vassilopoulos S, Vassilopoulos A, Kalligeros M, Shehadeh F, Mylonakis E (2022) Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with Anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis 9. https:\/\/doi.org\/10.1093\/ofid\/ofac574","DOI":"10.1093\/ofid\/ofac574"},{"key":"5517_CR36","doi-asserted-by":"publisher","unstructured":"Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R (2023) Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: a systematic review and meta-analysis. Leuk Res 131. https:\/\/doi.org\/10.1016\/j.leukres.2023.107324","DOI":"10.1016\/j.leukres.2023.107324"},{"key":"5517_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2021.05.038","volume":"154","author":"H Abid","year":"2021","unstructured":"Abid H, Wu JF, Abid MB (2021) Risk for infections with selinexor in patients with relapsed\/refractory multiple myeloma: a systematic review of clinical trials. Eur J Cancer 154:7\u201310. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.038","journal-title":"Eur J Cancer"},{"key":"5517_CR38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/01480545.2020.1835945","volume":"45","author":"Y Ling","year":"2022","unstructured":"Ling Y, Li R, Zhong J, Zhao Y, Chen Z (2022) Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis. Drug Chem Toxicol 45:1443\u20131448. https:\/\/doi.org\/10.1080\/01480545.2020.1835945","journal-title":"Drug Chem Toxicol"},{"key":"5517_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/hon.2706","volume":"38","author":"T Li","year":"2020","unstructured":"Li T, Timmins HC, King T, Kiernan MC, Goldstein D, Park SB (2020) Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials. Hematol Oncol 38:229\u2013243. https:\/\/doi.org\/10.1002\/hon.2706","journal-title":"Hematol Oncol"},{"key":"5517_CR40","doi-asserted-by":"publisher","unstructured":"Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR (2021) Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21. https:\/\/doi.org\/10.1186\/s12885-021-08451-x","DOI":"10.1186\/s12885-021-08451-x"},{"key":"5517_CR41","doi-asserted-by":"publisher","unstructured":"Reynolds G, Scheffer Cliff ER, Rehman Mohyuddin G, Midha S, Ng Liet Hing M, Harrison SJ, Kesselheim AS, Teh BW  Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Clinical trial registration information (if any): Infections following bispecific antibodies in myeloma: a systematic review and meta-1 analysis. 2. https:\/\/doi.org\/10.1182\/bloodadvances.2023010539\/2064732\/bloodadvances.2023010539.pdf","DOI":"10.1182\/bloodadvances.2023010539\/2064732\/bloodadvances.2023010539.pdf"},{"key":"5517_CR42","doi-asserted-by":"publisher","unstructured":"Georgoulis V, Haidich AB, Bougioukas KI, Hatzimichael E (2022) Efficacy and safety of carfilzomib for the treatment of multiple myeloma: an overview of systematic reviews. Crit Rev Oncol Hematol 180. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103842","DOI":"10.1016\/j.critrevonc.2022.103842"},{"key":"5517_CR43","doi-asserted-by":"crossref","unstructured":"Marquita, Camilleri Maria, Cuadrado Elizabeth, Phillips William, Wilson Richard, Jenner Gavin, Pang Sumaiya, Kamora Matthew, Streetly Rakesh, Popat Ceri, Bygrave Roger, Owen James, Cavenagh Mike, Chapman Jonathan, Sive Lydia, Eccersley Michael, Sheaff Reuben, Benjamin Karthik, Ramasamy Gordon, Cook Andres, Virchis Selina J., Chavda Laura, Clifton\u2010Hadley Marie Anne, Scully Kwee, Yong (2021) Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib cyclophosphamide and dexamethasone on the CARDAMON study Summary British Journal of Haematology 193(4) 750-760 10.1111\/bjh.v193.4 10.1111\/bjh.17377","DOI":"10.1111\/bjh.17377"},{"key":"5517_CR44","doi-asserted-by":"crossref","unstructured":"Despina, Fotiou Maria, Roussou Charikleia, Gakiopoulou Erasmia, Psimenou Maria, Gavriatopoulou Magdalini, Migkou Nikolaos, Kanellias Ioanna, Dialoupi Evangelos, Eleutherakis-Papaiakovou Stavroula, Giannouli Christina, Delavinia Kostantinos, Efstathiou Sofoklis, Kontogiannis Evangelos, Terpos Meletios A., Dimopoulos Efstathios, Kastritis (2020) Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients Abstract Blood Cancer Journal 10(11) 10.1038\/s41408-020-00381-4","DOI":"10.1038\/s41408-020-00381-4"},{"key":"5517_CR45","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, Wood J, Raynes K, Higgins H, Dawkins B, Meads D, Hulme CT, Monahan I, Karunanithi K, Dignum H, Belsham E, Neilson J, Harrison B, Lokare A et al (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol 20:1760\u20131772. https:\/\/doi.org\/10.1016\/S1470-2045(19)30506-6","journal-title":"Lancet Oncol"},{"key":"5517_CR46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NWCJ, Bruno B, Sezer O, Broij A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M et al (2015) European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 100:1254\u20131266. https:\/\/doi.org\/10.3324\/haematol.2014.117176","journal-title":"Haematologica"},{"key":"5517_CR47","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O\u2019Donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q et al (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9:e143\u2013e161. https:\/\/doi.org\/10.1016\/S2352-3026(21)00283-0","journal-title":"Lancet Haematol"},{"key":"5517_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/S41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, Lesokhin AM, Lonial S, Ludwig H, Moreau P, Patel K, Ramasamy K, Mateos MV (2023) Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 13:116\u2013116. https:\/\/doi.org\/10.1038\/S41408-023-00879-7","journal-title":"Blood Cancer J"},{"key":"5517_CR49","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"J Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser P, Lagrou K, Melchers WJG, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C, Agrawal S, Kibbler C, Pagliuca A, Ward K, Akova M, Herbrecht R et al (2016) ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71:2397\u20132404","journal-title":"J Antimicrob Chemother"},{"key":"5517_CR50","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/SJ.LEU.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blad\u00e9 J, Kyle R et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414\u2013423. https:\/\/doi.org\/10.1038\/SJ.LEU.2405062","journal-title":"Leukemia"},{"key":"5517_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","volume":"141","author":"F Al-Ani","year":"2016","unstructured":"Al-Ani F, Bermejo JMB, Mateos MV, Louzada M (2016) Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - a systematic review. Thromb Res 141:84\u201390. https:\/\/doi.org\/10.1016\/j.thromres.2016.03.006","journal-title":"Thromb Res"},{"key":"5517_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1743-7563.2011.01511.x","volume":"8","author":"M Alexander","year":"2012","unstructured":"Alexander M, Kirsa S, Mellor JD (2012) Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence. Asia Pac J Clin Oncol 8:319\u2013324. https:\/\/doi.org\/10.1111\/j.1743-7563.2011.01511.x","journal-title":"Asia Pac J Clin Oncol"},{"key":"5517_CR53","doi-asserted-by":"publisher","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","volume":"17","author":"A Li","year":"2019","unstructured":"Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, Gage BF, Garcia DA, Lyman GH, Sanfilippo KM (2019) Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw 17:840\u2013847. https:\/\/doi.org\/10.6004\/jnccn.2018.7273","journal-title":"J Natl Compr Canc Netw"},{"key":"5517_CR54","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","volume":"107","author":"V De Stefano","year":"2022","unstructured":"De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A, Offidani M, Petrucci MT, Ruggeri M, Santi RM, Barosi G (2022) Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica 107:2536\u20132547. https:\/\/doi.org\/10.3324\/haematol.2022.280893","journal-title":"Haematologica"},{"key":"5517_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/HEMATOLOGY.2022000414","volume":"2022","author":"F Covut","year":"2022","unstructured":"Covut F, Sanfilippo KM (2022) Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy. Hematology Am Soc Hematol Educ Program 2022:363. https:\/\/doi.org\/10.1182\/HEMATOLOGY.2022000414","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5517_CR56","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ajh.25603","volume":"94","author":"KM Sanfilippo","year":"2019","unstructured":"Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 94:1176\u20131184. https:\/\/doi.org\/10.1002\/ajh.25603","journal-title":"Am J Hematol"},{"key":"5517_CR57","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/BLOOD.2022015727","volume":"140","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty R, Rybicki L, Wei W, Valent J, Faiman BM, Samaras CJ, Anwer F, Khorana AA (2022) Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood 140:2443\u20132450. https:\/\/doi.org\/10.1182\/BLOOD.2022015727","journal-title":"Blood"},{"key":"5517_CR58","doi-asserted-by":"publisher","unstructured":"Fotiou D, Gavriatopoulou M, Terpos E (2020) Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/CANCERS12010191","DOI":"10.3390\/CANCERS12010191"},{"key":"5517_CR59","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/S41375-018-0040-1","volume":"32","author":"H Ludwig","year":"2018","unstructured":"Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X et al (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 32:1542. https:\/\/doi.org\/10.1038\/S41375-018-0040-1","journal-title":"Leukemia"},{"key":"5517_CR60","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","volume":"129","author":"M Delforge","year":"2017","unstructured":"Delforge M, Ludwig H (2017) How i manage the toxicities of myeloma drugs. Blood 129:2359\u20132367. https:\/\/doi.org\/10.1182\/blood-2017-01-725705","journal-title":"Blood"},{"key":"5517_CR61","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3324\/haematol.2009.012674","volume":"95","author":"B Mohty","year":"2010","unstructured":"Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M (2010) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 95:311\u2013319","journal-title":"Haematologica"},{"key":"5517_CR62","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/BLOOD-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112:1593\u20131599. https:\/\/doi.org\/10.1182\/BLOOD-2008-04-149385","journal-title":"Blood"},{"key":"5517_CR63","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113\u20133120. https:\/\/doi.org\/10.1200\/JCO.2005.04.7779","journal-title":"J Clin Oncol"},{"key":"5517_CR64","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","volume":"144","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blad\u00e9 J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144:895\u2013903. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07573.x","journal-title":"Br J Haematol"},{"key":"5517_CR65","doi-asserted-by":"publisher","unstructured":"Page MJ, Moher D, Fidler FM, Higgins JPT, Brennan SE, Haddaway NR, Hamilton DG, Kanukula R, Karunananthan S, Maxwell LJ, McDonald S, Nakagawa S, Nunan D, Tugwell P, Welch VA, McKenzie JE (2021) The REPRISE project: protocol for an evaluation of reproducibility and replicability in syntheses of evidence. Syst Rev 10. https:\/\/doi.org\/10.1186\/s13643-021-01670-0","DOI":"10.1186\/s13643-021-01670-0"},{"key":"5517_CR66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","volume":"23","author":"M Noori","year":"2023","unstructured":"Noori M, Yazdanpanah N, Rezaei N (2023) Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell Int 23:193. https:\/\/doi.org\/10.1186\/s12935-023-03045-y","journal-title":"Cancer Cell Int"},{"key":"5517_CR67","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","volume":"7","author":"F Mazahreh","year":"2023","unstructured":"Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S (2023) Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv 7:3069\u20133074. https:\/\/doi.org\/10.1182\/bloodadvances.2022009435","journal-title":"Blood Adv"},{"key":"5517_CR68","doi-asserted-by":"publisher","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S (2020) Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 13. https:\/\/doi.org\/10.1186\/s13045-020-01001-1","DOI":"10.1186\/s13045-020-01001-1"},{"key":"5517_CR69","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G et al (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 24:e255\u2013e269. https:\/\/doi.org\/10.1016\/S1470-2045(23)00159-6","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05517-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05517-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05517-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:04:39Z","timestamp":1722060279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05517-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5517"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05517-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}